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Abstract
Background A gap analysis was conducted to determine which
areas of breast cancer research, if targeted by researchers and
funding bodies, could produce the greatest impact on patients.
Methods Fifty-six Breast Cancer Campaign grant holders and
prominent UK breast cancer researchers participated in a gap
analysis of current breast cancer research. Before, during and
following the meeting, groups in seven key research areas
participated in cycles of presentation, literature review and
discussion. Summary papers were prepared by each group and
collated into this position paper highlighting the research gaps,
with recommendations for action.
Results Gaps were identified in all seven themes. General
barriers to progress were lack of financial and practical
resources, and poor collaboration between disciplines. Critical
gaps in each theme included: (1) genetics (knowledge of
genetic changes, their effects and interactions); (2) initiation of
breast cancer (how developmental signalling pathways cause
ductal elongation and branching at the cellular level and
influence stem cell dynamics, and how their disruption initiates
tumour formation); (3) progression of breast cancer
(deciphering the intracellular and extracellular regulators of early
progression, tumour growth, angiogenesis and metastasis); (4)
therapies and targets (understanding who develops advanced
disease); (5) disease markers (incorporating intelligent trial
design into all studies to ensure new treatments are tested in
patient groups stratified using biomarkers); (6) prevention
(strategies to prevent oestrogen-receptor negative tumours and
the long-term effects of chemoprevention for oestrogen-
receptor positive tumours); (7) psychosocial aspects of cancer
(the use of appropriate psychosocial interventions, and the
personal impact of all stages of the disease among patients from
a range of ethnic and demographic backgrounds).
Conclusion Through recommendations to address these gaps
with future research, the long-term benefits to patients will
include: better estimation of risk in families with breast cancer
and strategies to reduce risk; better prediction of drug response
and patient prognosis; improved tailoring of treatments to
patient subgroups and development of new therapeuticPage 1 of 25
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resources for screening populations; and an enhanced
experience for people with or at risk of breast cancer and their
families. The challenge to funding bodies and researchers in all
disciplines is to focus on these gaps and to drive advances in
knowledge into improvements in patient care.
Introduction
Significant advances in the prevention, diagnosis and manage-
ment of breast cancer have been made in recent years based
on the clinical application of scientific discoveries. However,
breast cancer remains a complex disease process affecting
millions worldwide, and further advances in scientific knowl-
edge and clinical care could improve many lives. It is timely to
review the current position of breast cancer research because
funding bodies, researchers and clinicians work in an exciting
age of discovery but have limited resources.
In November 2006, the research charity Breast Cancer Cam-
paign convened a panel of leading breast cancer researchers,
as an initial event, to debate and identify the limitations of cur-
rent research into the pathophysiology, detection, treatment,
prevention and psychosocial aspects of breast cancer. The
aims of this analysis were as follows: To determine the gaps in
our knowledge of breast cancer that, if resolved, could result
in benefits to patients; To encourage breast cancer research-
ers and funding bodies worldwide to focus their resources on
the highlighted areas of research to achieve a substantive
impact for patients; To make recommendations for priority
action.
This gap analysis represents a unique insight into breast can-
cer research in the UK and the challenges involved in directing
efforts to areas in need of further investigation likely to result in
advances in the management of breast cancer.
Materials and methods
Current and former members of the Breast Cancer Campaign
Scientific Advisory Board leading scientists and clinicians res-
ident in the UK were invited to participate in the gap analysis
meeting. The choice of participants was based on publication
record, research activity and clinical stature, and selected
using a database of researchers developed since the incep-
tion of the Breast Cancer Campaign in 1988.
Seven key research areas were selected for review in the gap
analysis by the Breast Cancer Campaign and the Scientific
Advisory Board, taking into account UK, European and USA
themes in scientific meetings focused on breast cancer and
UK Government analyses of research funding streams: Genet-
ics of breast cancer; Initiation of breast cancer; Progression of
breast cancer; Therapies and targets in breast cancer; Dis-
ease markers in breast cancer; Prevention of breast cancer;
Psychosocial aspects of breast cancer.
Prior to the event, participants were asked to review relevant
literature and construct short presentations summarising their
areas of expertise and identifying potential research gaps. Key
participants had already conducted, published and/or
reviewed systematic evidence, literature reviews and evi-
dence-based guidelines. As a result they were considered to
be opinion leaders in their field. Further, additional, systematic
literature reviews for each of the seven areas under consider-
ation was not performed.
For each theme, 6 to 10 UK breast cancer researchers of
national or international standing in their fields of research
were invited and accepted participation in the event. Twenty-
three invitees declined to contribute to the gap analysis.
On 2 November 2006 a one-day meeting was convened in
London, UK. In the initial subgroup sessions, each participant
gave a presentation to their group on pre-agreed topics rele-
vant to the gap analysis for their assigned breast cancer
research area on which they were experts. There were con-
structive debates of the content and the issues raised by the
presentations were explored further. Breast Cancer Campaign
staff members acted as facilitators throughout the analysis
process.
Issues explored during the gap analysis were structured
around the following questions: What do we already know;
What are the gaps in our knowledge; What are the problems
that need to be overcome to fill these gaps; What are the
translational implications?
After collating the information resulting from these discussions
for each of the seven themes, this four-point structure was
used to present the content of each theme to the other partic-
ipants and to discuss their findings in an open forum.
This iterative process continued as evidence-based expert
opinion from the one-day meeting was cross-referenced,
shaped and developed during subsequent weeks. Each group
formulated a summary paper for their research area, incorpo-
rating key references, which was then circulated to the partic-
ipants of the respective groups for further refinement. These
seven themes were collated into a unified position paper,
which is what we present here.
Results and discussion
1. Genetics of breast cancer
A summary of the gap analysis for the genetics of breast can-
cer is given in Table 1.Page 2 of 25
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Several genes bearing high-penetrance mutations have been
implicated in inherited predisposition to breast cancer, the
most important of these being in the BRCA1 and BRCA2
genes. However, BRCA1 and BRCA2 account for less than
5% of all breast cancer and, in recent years, breast cancer
susceptibility genes other than BRCA1 and BRCA2 have
been identified. These genes fall into two broad categories:
Those containing rare moderate-penetrance alleles such as
CHEK2, ATM and BRIP1 [1-3]; Those carrying more common
low-penetrance alleles [4].
Large genome-wide association and candidate gene studies
to identify the latter are just beginning to bear fruit [5-8].
Intermediate phenotypes such as radiosensitivity and mammo-
graphic density have quite strong genetic components and
further study of these may provide some insight into novel
breast cancer susceptibility genes.
Since the breast cancer genes BRCA1 and BRCA2 were
cloned in 1994 and 1995, respectively, research efforts have
concentrated on developing an understanding of the cellular
functions of the large multidomain proteins encoded by
BRCA1 and BRCA2 and the mechanisms by which loss of
their functions causes breast cancer. An understanding of
these mechanisms is relevant not only to families with BRCA1
and BRCA2 mutation carriers but also in sporadic breast can-
cer, in which the same or related genetic pathways may also
be aberrant.
Cells deficient in BRCA1 and BRCA2 are extremely sensitive
to DNA-damaging agents and are defective in repairing DNA
double-strand breaks by homologous recombination, being
impaired in the recruitment and filament formation of the
recombination protein RAD51 [9,10]. More recently, new
functions have been identified for both proteins: BRCA1 and
its partner BARD1 form an E3-ubiquitin ligase that is recruited
to sites of DNA damage and activated by the DNA damage
checkpoint, promoting ubiquitylation [11]. The first in vivo sub-
strate for such ubiquitylation events has been identified as
CtIP [12].
An important development in recent years has been the iden-
tification of the links between the BRCA1 and BRCA2 path-
ways and proteins involved in Fanconi anaemia. Several genes
cause Fanconi anaemia, and most of these encode proteins
that are involved in a complex that ubiquitylates FANCD2 at
Table 1
Summary of the gap analysis for the genetics of breast cancer
What do we know? Multiple genes of different penetrance are involved in the predisposition 
to breast cancer.
Genome wide screens and somatic genetic approaches are identifying 
further genes involved in breast cancer.
What are the gaps? Detailed understanding of the actions of BRCA1 and BRCA2.
Knowledge of large-scale genetic rearrangements in tumour cells.
The important variants, effects and interactions of low-penetrance 
genes.
Further identification of point mutations and epigenetic changes.
Problems The quality, quantity and accessibility of materials.
Funding for large-scale experiments (such as sequencing) using 
expensive equipment.
Bioinformatic analysis skills.
Translational implications Classifying breast tumours according to the signalling pathways that 
are disrupted to predict prognosis and response to therapy.
Determining the relevance of somatic events to prognosis and 
response to therapy.
Generate new, targeted therapies based on target discovery.
Better genetic risk estimation.
Recommendations Encourage development of research techniques to allow integrated 
analysis of sequence level, epigenetic and large-scale somatic 
changes.
Engage in national initiatives for activities such as high-throughput re-
sequencing and UK controls.
Encourage research involving intermediate phenotypes.Page 3 of 25
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downstream of this step. FANCD1 was found to be the
BRCA2 gene [13]. FANCJ encodes BRIP1, which interacts
with the BRCT domain of BRCA1 and, of note, mutations in
this gene can also cause breast cancer [3]. Lastly, FANCN
encodes PALB2, which interacts with BRCA2, and is also a
breast cancer susceptibility gene [14].
What are the gaps?
There remain gaps in our knowledge of cancer predisposition
genes, both in identifying genes responsible for low-pene-
trance disease and the interactions with environmental factors.
Increasing knowledge of BRCA1 and BRCA2 acts as an
exemplar resulting in improved patient care. However, defi-
ciencies remain in our understanding of how BRCA1 or
BRCA2 dysfunction causes breast cancer, for example, it is
unclear why BRCA1 deficiency is associated with triple-nega-
tive (basal-like) breast cancer. We also need to find other pro-
teins that interact with BRCA1 and BRCA2 and elucidate the
post-translational modifications that occur as a result of these
interactions. For example, the functional consequences of
CtIP ubiquitylation and its implications for RAD51 recruitment
are not yet known; furthermore, it is likely that there are other
substrates for BRCA1/BARD1.
Only a relatively small proportion of breast cancers are caused
by the loss of BRCA1 or BRCA2 function; most arise as a
result of somatic mutation or changes in expression of a
number of other genes. The list of genes showing somatic
point mutations in breast cancers is beginning to be identified
using genome-wide sequencing approaches [15]. Epigenetic
changes such as DNA methylation and histone modification
can cause loss or gain of gene expression, and genome-wide
screens for these are being actively pursued. More work is
needed in both of these areas.
To date, little progress has been made towards cataloguing
larger-scale genetic rearrangements, such as translocations,
deletions and amplifications, which occur frequently and are
the hallmarks of tumour cells and have been particularly useful
in the haematological malignancies. These changes also need
to be related to tumour subtype. Reciprocal translocations
seem to be common; for example, one translocation causes
abnormal expression of the NRG1 gene which encodes lig-
ands of the epidermal growth factor receptor (EGFR) family
[16]. Work has begun to characterise and catalogue these
events using high-resolution DNA microarrays. In the future it
will be important to devise approaches to examine sequence-
level, epigenetic and large-scale changes together and relate
these to clinical features to form a complete and integrated
picture.
As common, low-penetrance alleles continue to be identified,
future challenges lie in identifying the causative variants within
the haplotype blocks containing the associated marker single
nucleotide polymorphism (SNP). First, this requires high-
throughput sequencing capacity to detect all common variants
in haplotype blocks spanning typically 30 to 150 kb, in at least
48 people. Second, case and control DNA collections from
non-European populations are needed to separate alleles that
are completely correlated in European populations. Third, sen-
sitive biological assays need to be developed to determine the
differences in function of the potentially causative alleles. It will
be important to encourage a high degree of collaboration
between research groups, in particular between epidemiology
and basic biology. Furthermore, these studies would benefit
from shared resources including first-class sample collections,
such as a UK national control set.
A potentially useful but currently under-developed approach is
to examine other phenotypes linked with breast cancer that are
themselves determined genetically. These include mammo-
graphic density, radiation sensitivity, cell migration and circu-
lating levels of hormones and growth factors.
What are the problems?
The number of patients required for gene searches requires
large national and international consortia. The quality, quantity
and form of the clinical material (blood derivatives, frozen tis-
sue, formalin fixed tissues), and the handling or products from
these present a significant challenge. The increasing sophisti-
cation of equipment and the level of technical expertise are
reflected in the need to integrate the data in a meaningful way
presenting a substantial bioinformatics challenge. Techniques
for high-throughput re-sequencing are being developed, but
funding is needed to make these accessible. Thus, this type of
research is particularly resource intensive and requires a high
level of collaboration.
Translational implications
Therapies based on developing an understanding of the role
of BRCA1 and BRCA2 in DNA repair are already in clinical tri-
als (including cisplatin and PARP inhibitors), and improving
our understanding of the many functions of BRCA1 and
BRCA2 will no doubt generate further targets for therapy.
Increasing efforts to understand genetic events should allow
us to perform the following functions: Classify breast tumours
according to the signalling pathways that are disrupted and to
predict prognosis and response to therapy; Determine the rel-
evance of somatic events to prognosis and response to ther-
apy; Generate new, targeted therapies based on target
discovery.
Identifying combinations of inherited variants that predispose
to breast cancer will allow us to better estimate risk in families
with breast cancer and help to characterise defective signal-
ling pathways. DNA collections from cancer prevention trials
and clinical trials of radiotherapy and chemotherapy are under-
way to relate DNA variants to treatment response. While the
trial populations of the UK, Europe and the US may providePage 4 of 25
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tion should enhance future patient management.
2. Initiation of Breast Cancer
A summary of the gap analysis for the initiation of breast can-
cer is given in Table 2.
To decipher the molecular basis of the initiation and progres-
sion of breast cancer, it is critical that we fully understand the
key features and genes involved in normal mammary develop-
ment. Changes to developmental processes may lead to
tumour initiation and the influences of endocrine agents,
growth factors and environmental carcinogens on normal and
developing breast components is largely unknown,
What do we know?
Significant progress has been made in determining the local
factors that control all stages of mammary development,
largely through the generation of an extensive array of trans-
genic and knockout mouse strains [17]. Such animal models
are complemented by classic embryological approaches that
enable the transplantation of a complete mammary gland, duc-
tal rudiments or, more recently, stem cells into cleared fat pads
[18-20]. These approaches have imparted considerable
knowledge about a wide array of developmental signalling
pathways that are now known to be dysregulated in tumours.
For example, amphiregulin/EGFR signalling is required for the
branching and outgrowth of the ductal epithelial tree during
pubertal development [21,22], while overexpression of both
the ligand and receptor, and the related receptor ErbB2, is
associated with poor prognosis in breast cancer [23]. Other
examples include the IGF, integrin, Notch, NF-κB, STAT, TGF-
β and Wnt pathways [24-29].
What are the gaps?
Tissue architecture
Many of the signalling pathways controlling normal mammary
development have been identified and the genetic circuit dia-
grams that link the different pathways are emerging [17]. How-
ever, it is not clear how these signals cause ductal elongation
or branching at the cellular level, or even how they maintain
normal ductal or acinar architecture. Although analysis has
focused on epithelial cells, the stromal, endothelial and
immune components are also crucial for development [30].
For example, fibroblasts and macrophages are required for
ductal growth [31]. However, many of the stroma-derived sig-
nals are poorly understood, as is the reciprocal communica-
tion between the epithelium and stroma and the signalling
pathways controlled by the interaction between luminal and
myoepithelial cells.
In addition, the importance of cell adhesion and the extracellu-
lar matrix has been underestimated, although it is becoming
increasingly clear that both adhesion and matrix-derived sig-
nals modify many signalling pathways and provide a spatial
Table 2
Summary of the gap analysis for the initiation of breast cancer
What do we know? Animal models have given us great insight into the molecular pathways involved in breast development and 
dysregulation in cancer.
What are the gaps? The relationship of signalling pathways to ductal and acinar breast architecture.
The need for widespread use of more appropriate in vivo and culture methods.
The importance of stroma and other cell types, cell adhesion and the extracellular matrix.
Understanding stem cells.
Understanding mechanisms of epithelial apoptosis.
Understanding how pregnancy and functional differentiation in the breast protect against breast cancer.
Problems The breast cell lines used and their culture conditions.
A wider variety of promoters with spatial, temporal and differentiation control of gene expression is needed.
The need for mouse models of specific breast cancer types, for example, triple negative breast cancer.
The implantation methods for single cells in vivo.
Translational implications Understanding the complex interactions between cell types should provide new opportunities for intervention.
Identifying pre-invasive changes has implications for patient-tailored approaches.
Recommendations Develop three-dimensional cell culture models, containing multiple cell types, which reflect the tissue architecture of 
the normal and diseased breast.
Generate better animal models, in which gene expression can be manipulated in each cell type of the mammary gland 
and will not be altered by transdifferentiation or dedifferentiation.
Gain a greater understanding of the genetic changes that occur within atypias and DCIS.Page 5 of 25
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changes in cell adhesion, through matrix remodelling or altered
adhesion receptors, underpin both tissue disorganisation in
early breast cancer and progression to malignancy [33,34],
but their involvement in tumour initiation is not well
understood.
Stem cells
The recent development of technologies allowing enrichment
of mammary gland stem cells has been a significant step for-
ward [19,20,35]. However, it is still not possible to purify these
cells to homogeneity, and we do not fully understand their
location within the ducts or the mechanisms involved in their
differentiation into luminal and myoepithelial cells [36,37].
Moreover, it is not certain whether cancer stem cells are
derived from normal stem cells or an intermediate progenitor
cell, or how they are influenced by stromal factors [38]. In fact,
it is far from clear that tumours are derived from stem/progen-
itor cells at all, as opposed to reprogrammed differentiated
cells, let alone whether differences between cancer stem cells
might be responsible for the development of different tumour
subtypes.
Although considerable progress has been made towards
understanding the mechanisms controlling epithelial apopto-
sis in the mammary gland, we know little about the sensitivity
of stem/progenitor cells to apoptosis signals [39,40]. Cells of
the main ducts survive involution, while alveoli and terminal
ducts are lost, although the reason for this difference is not
clear.
We also have little understanding of how early pregnancy and
functional differentiation of the breast protects against cancer,
and whether this is related to stem cell dynamics [41].
Consequently, we urgently need more appropriate in vivo and
culture models to resolve the mechanisms of both normal
breast development and tumour initiation. Furthermore, use of
these sophisticated models needs to become more
widespread.
What are the problems?
Culture models
Breast cancer has traditionally been studied by cell and molec-
ular biologists using long-lived cell lines that are derived from
late stage tumours and which display few of the cellular prop-
erties of normal breast epithelial cells. In addition, we now
appreciate that breast cancer involves growth in three dimen-
sions and the contribution of various breast cell types. Further-
more, techniques for studying the initiation and progression of
cancer are largely restricted to analysing the luminal epithe-
lium. Recently there has been a shift from two-dimensional to
three-dimensional culture models, which better reflect the tis-
sue environment found in vivo [42,43]. However, most of
these models still contain only luminal epithelial cells. In the
future, culture models containing all mammary cell types, as
well as those amenable to examining ductal branching, model-
ling the stem cell niche and even assessing whether an iso-
lated cell is a stem cell, will provide fertile avenues for analysis
[44].
Excellent imaging technologies are emerging to explore the
dynamic nature of mammary gland development and neoplasia
both in culture and in vivo; applying them to human cancer
cells and ensuring their widespread use will be of enormous
value [45,46].
Genetic analyses
Expression of transgenes or gene ablation specific to the
mammary gland is usually achieved by placing the transgene
or Cre recombinase under the control of a milk gene promoter
or the MMTV promoter [47]. However, these promoters are
active only in the luminal epithelium and, in the case of the milk
protein genes, limited to a particular developmental stage.
More recently, the keratin 5 promoter has been used to target
myoepithelial and basal cells [48]. Despite this, a wider variety
of promoters would improve the spatial and/or temporal con-
trol gene of expression. This will be helped considerably by
generating an atlas of mammary gland development. Further
refining markers to identify stem and progenitor cells, and
fibroblasts, will pinpoint other valuable promoters. Greater use
of inducible transgene systems, such as the Tet-On system,
will allow transgene expression to be restricted to specific time
intervals [49].
Another significant problem with existing promoters is that
their expression in the luminal epithelium depends on its differ-
entiation; activity is therefore lost if a transgene causes
transdifferentiation or dedifferentiation within a tumour. The
problem can be overcome through the development of 'hit and
run' transgenics. These include lines where the expression of
a transgene is under the control of a housekeeping gene but
is prevented by a lox-stop-lox cassette. Excision of the stop
codon by crossing with mice carrying a gland-specific Cre
recombinase then leads to continuous and consistent trans-
gene expression. These and similar sophisticated strategies
will allow the more realistic activation of breast cancer onco-
genes, and will provide better opportunities to understand
how they cause disease within the correct tissue environment.
It would also be valuable to produce a series of transgenic
reporter gene mice equivalent to the TOPGAL strain, to moni-
tor changes in developmental signalling pathways [50].
There will also be great benefit in generating better mouse
models of specific types of human breast cancer, ranging from
triple negative breast cancer (oestrogen receptor negative,
progesterone receptor negative and HER2 negative) to oes-
trogen receptor positive tumours. Similarly, straightforward
protocols for implanting and growing primary human cancer
cells in the cleared mammary fat pad of immunocompromisedPage 6 of 25
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erating such humanised models, but it is still not possible to
implant individual cells [51].
Translational implications
Continuing to study normal breast development will provide
many useful insights into the earliest stages of breast cancer
initiation. Tumour development depends on signals between
the stroma, myoepithelial cells and luminal cells, and therefore
gaining a better understanding of how these cells communi-
cate in normal mammary gland and early breast disease will
provide new opportunities for intervention.
In addition, we know little about the genetic changes that
occur in atypias, lobular or ductal carcinoma in situ (DCIS)
[52], although they are most likely to be within components of
the signalling pathways that control normal development. Pro-
ducing timelines of these mutations for different breast cancer
subtypes, similar to those generated for colon cancer [53],
would be a major step forward. Molecular profiling of breast
cancers has begun to classify tumours [54], and relating them
to the TNM classification will be clinically valuable for biomar-
ker analysis and therapy. Differences between profiles may
represent alterations in specific signalling pathways, so map-
ping this information onto a timeline of when mutations occur
in breast cancer will enable clinicians to tailor specific treat-
ments to individuals.
3. Progression of Breast Cancer
A summary of the gap analysis for the progression of breast
cancer is given in Table 3.
Intracellular inputs
What do we know?
The oestrogen receptor, receptor tyrosine kinase (RTK) and
DNA repair pathways are key research areas in understanding
the intracellular inputs for growth and progression of invasive
breast cancer.
Table 3
Summary of the gap analysis for the progression of breast cancer
What do we know? Oestrogen receptor, receptor tyrosine kinase (RTK) and DNA repair pathways have been researched extensively.
Around 50% of DCIS will progress to invasive disease if untreated, with 12% to 20% recurring at 10 years despite 
appropriate treatment.
What are the gaps? Understanding the complexities of breast cancer intracellular signal transduction pathways, paracrine pathways, 
invasion, angiogenesis and metastasis including relevance of these mechanisms to clinical progression.
Whether there are inherently migratory stem cells or is metastatic capacity acquired.
Understanding time-dependent progression events, notably dormancy and reactivation of micrometastasis, at 
particular secondary sites.
Understanding the emerging relationship between therapeutic resistance and metastasis.
Causative factors underlying recurrence of DCIS or progression to invasive disease
Understanding the interplay between stroma, myoepithelial and epithelial components during early progression and 
interplay between tumour cells, stroma and the immune system in metastasis.
The need for improved preclinical models of the influences of the microenvironment, site-specific metastasis and 
dormancy.
In vivo imaging technologies to study the dynamics of metastasis and relate this to signalling mechanisms, as well as 
means to manipulate these mechanisms to evaluate targeting potential.
Problems Appropriate clinical samples to evaluate biomarkers and cellular endpoints.
Appropriate preclinical models and improved research reagents.
Increasingly complex and multidisciplinary research infrastructure.
Translational implications Identifying patients at increased risk of dissemination.
Effectively predict therapeutic response with growth inhibitors.
Improve selection of patients with DCIS for adjuvant radiotherapy or endocrine therapies.
Identify cellular targets for developing new agents to target breast cancer progression effectively and selectively.
Recommendations Improve preclinical models, research reagents and technologies (including imaging).
Enhance access to appropriate clinical material, notably matched samples during progression and sequential samples 
obtained during treatments including new agents.
Consider the genetic signature/specific genetic lesions when exploring progression biology and designing clinical 
trials.Page 7 of 25
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tor alpha (ERα) input, a fundamental driver for the growth of
many breast cancers, should not be considered independent
of additional signalling networks. This nuclear ERα may inter-
play with ERβ and there is emerging evidence that membrane-
localised ERα may also have a role. A web of RTK signalling
also contributes to breast cancer growth and progression, and
these pathways can interact with ER when present [55-57].
Previous experimental deciphering of ER and RTK pathways
has provided proof of principal that useful biomarkers and ther-
apies (for example, endocrine therapies, erbB and kinase
inhibitors) can stem from concerted research in breast cancer
growth signalling biology [58].
DNA damage response (DDR) pathways and mechanisms for
mitotic chromosome segregation are also of interest when
considering breast cancer growth, progression and selectivity.
They can be subject to genetic alteration, associating with
tumourigenesis for inherited (for example, BRCA proteins) and
for sporadic (for example, Aurora A: 30% to 60% overexpres-
sion) breast cancer because they cause genetic instability that
may permit secondary alteration, accelerating the develop-
ment of cancer. Equally, there are major implications for thera-
peutic efficacy, for example, for poly(ADP-ribose) polymerase
inhibitors and BRCA mutations, and also resistance to taxanes
when Aurora A is amplified [59].
What are the gaps?
Research into ER and RTK signalling is intense. Further deci-
phering of the complexities of breast cancer signal transduc-
tion pathways, their regulation and interplay, including
elucidating downstream gene effects, is important, not least
because therapeutic resistance is a persistent problem for all
therapies targeting known pathways.
There are also limitations in our ability to subsequently evalu-
ate RTK and ER signalling aspects emerging from experimen-
tal studies in clinical disease and to rapidly translate findings
into clinically useful biomarkers and targets for new drug
development.
Furthermore, the breadth of DDR and mitotic regulator altera-
tions underlying the pathogenesis of breast cancer and its
subtypes, or the point at which DDR alterations might contrib-
ute to disease progression is unknown.
Extracellular inputs
What do we know?
Local paracrine pathways (for example, those involving
TGFβs), cell invasion into the extracellular matrix and angio-
genesis all contribute to cancer growth and metastasis. Selec-
tive inhibitors of anti-Src and anti-HGF/Met, for some of the
identified pathways involved in metastasis and inhibition of
angiogenesis (for example, by targeting vascular endothelial
growth factor signalling) are already in clinical practice [60].
What are the gaps?
Substantial questions remain about the biology of angiogen-
esis and metastasis. While studies of aggressive breast can-
cer cells in vitro have allowed significant progress in
understanding adhesion and migration through matrix, matrix
degradation (including mechanisms of matrix
metalloproteinases) and in vitro invasiveness, subsequent
translational applications have proved limited.
We have yet to fully explore the breadth of potential positive
and negative regulators of invasion and metastasis, their
mechanisms and interplay, and the role of the interaction of
tumour cells with the stromal microenvironment and immune
system during metastasis. The propensity for cancer to metas-
tasise, apparently selectively, to certain end organs is poorly
understood. Whether human breast cancers contain inher-
ently migratory stem cells or whether metastatic capacity is
acquired, and also time-dependent progression events, nota-
bly dormancy and reactivation of micrometastasis at particular
secondary sites, remain poorly defined.
Equally, little is known about the emerging relationship
between resistance to conventional therapies (for example,
endocrine therapies) and metastasis [61] or the degree of
redundancy of invasive elements or angiogenic pathways that
may contribute to therapeutic resistance to anti-invasive and
anti-angiogenic approaches.
Ductal carcinoma in situ and very early progression in breast 
cancer
What do we know?
Around 50% of DCIS will progress to invasive disease if
untreated, with 12% to 20% recurring locally at 10 years
despite breast conserving surgery and radiotherapy. Links
have been suggested between early progression and mecha-
nistic alterations both within the epithelial cells and in the inter-
play with associated basement membrane, myoepithelial and
stromal cells, and mechanical constraints [62,63]. HER2 pos-
itivity and HER4 negativity, and high levels of cyclo-oxygenase-
2 (COX-2) may have some relevance to invasive recurrence
[64].
What are the gaps?
There is still a substantial gap in our knowledge of the causa-
tive factors underlying progression of DCIS to invasive disease
and, in general, there are no compelling biomarkers that can
robustly predict invasive recurrence. We also lack biomarkers
that can select for patients who might benefit from existing
therapies, since ER and HER2 (and EGFR) status are not rou-
tinely measured in DCIS outside clinical trials and so treatment
is currently based on morphological assessment. Equally,
there are few targets in DCIS to subvert progression other
than ER for ER positive DCIS, with ER-negative DCIS thus
being particularly problematic.Page 8 of 25
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reflect those for invasive breast cancer. There are substantial
gaps in our ability to perform biological investigation of the
intracellular and extracellular factors (notably interplay among
stroma, myoepithelial and epithelial components) underlying
growth and progression of DCIS, to dynamically monitor early
progression, and to subsequently manipulate implicated path-
ways to address their therapeutic potential.
What are the problems?
Improved preclinical models
We need to develop better preclinical models in order to more
accurately reveal the mechanisms involved in growth and
progression of breast cancer and to evaluate potential targets.
This is particularly important when trying to interpret the mech-
anisms of metastasis because dissemination commonly
occurs at inaccessible sites, making clinical research material
extremely difficult to obtain. However, it is equally relevant if we
are to build on findings made using in vitro monolayer culture
studies for growth signalling mechanisms.
Models are needed to allow researchers to investigate more
accurately the influence of the microenvironment, the impact
of the immune system and site-specific metastasis, and time-
dependent progression including the phenomenon of dor-
mancy. In vivo models will be essential to study these areas,
and researchers may also benefit from in vitro three-dimen-
sional assays encompassing stromal components, matrix and
tumour epithelial cells [65], as well as studies over extended
culture time in vitro and associated animal models.
Increased use of genetically modified animal models will be
valuable, as will genetic manipulation of individual targets (for
example, using RNAi) alone or in combination with existing
agents in model systems to address how mechanisms of
growth and spread might be exploited to provide new targeted
therapies. Studies of very early progression will also require
improved models, notably use of in vitro cultures of primary or
mammosphere DCIS (again extending to longer-term culture),
and of human DCIS xenograft and transgenic (for example,
MMTV/HER2) models.
Alongside targeting individual candidate elements, more spec-
ulative approaches are warranted to broadly screen for syn-
thetic lethality, for example, using RNAi libraries. We also need
to embrace fully in vivo imaging technologies to decipher the
dynamics of metastasis (and equally of very early progression)
at a cellular level and relate this to signalling mechanisms (for
example, using in vivo fluorescent reporter assays).
Powerful real-time imaging studies in animal models are
emerging which indicate that the motile phenotype may be
transient and confined to a subpopulation of cells at the
tumour periphery in disease metastasising in vivo. Such heter-
ogeneity is not easily modelled with in vitro studies. These
observations illustrate the power of imaging systems for deci-
phering breast cancer biology, where the data have implica-
tions for interpreting whole tumour microarray/proteomic
profiles and clearly confirm that time-dependent study of
metastasis at a cellular level is essential.
Appropriate clinical samples
Appropriate clinical samples are needed to translate experi-
mental findings into useful predictive biomarkers, and to con-
firm that therapeutic strategies stemming from basic research
are relevant in patients. Meaningful study will require, where
possible, improved access to clinical material with parallel
therapeutic response and survival data, encompassing tissue
microarray (TMA) and full-section resources. Studies will ben-
efit from improved access to clinical samples of primary, local
recurrent, lymph node and distant metastatic (where accessi-
ble) breast cancer, ideally comparing matched samples from
patients to track potential biomarkers of progression. Studies
of very early progression will also need increased access to
clinical DCIS material to verify the relevance of experimental
associations with invasive recurrence, considering gene
expression signatures both for DCIS and invasive disease,
preferably from the same patient.
It is also important that researchers obtain material from
sequential samples (with parallel outcome data), taken before
and during treatment with conventional therapies, and from
biologically directed innovative trials of targeted therapies.
Clinical trial design should increasingly incorporate improved
tissue collection and pathology support (which has often been
considered as an afterthought). Experience indicates that neo-
adjuvant studies and, where possible, access to patient sam-
ples treated longer term will be particularly valuable.
Studying samples obtained during treatment with anti-invasive
agents (or, indeed, any new agents) will allow researchers to
evaluate the ability of biomarkers and cellular endpoints stem-
ming from experimental studies to provide surrogates for drug
response, an important aim in the absence of long-term out-
come data. This could be achieved by examining circulating
tumour cells and sampling lymph nodes during treatment. In
addition, evaluation of anti-invasive agents could benefit signif-
icantly from improvements in tumour tissue imaging of func-
tional reporters.
These needs for clinical tissue clearly represent a significant
challenge, particularly given that research must comply with
ethical and legal considerations. To be achievable, patient
recruitment to trials must be improved and the collection and
sharing of tissue resources must be coordinated. For DCIS
studies, sequential clinical samples taken pre-operatively dur-
ing treatment with currently available agents (endocrine thera-
pies, erbB or COX-2 inhibitors) or with emerging new
therapies, are needed to confirm mechanisms and predictivePage 9 of 25
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 2    Thompson et al.capacity, and so enhanced trial design and better recruitment
of DCIS patients is also essential.
Consideration of gene profiles
Greater attention needs to be given to gene profiles and the
impact of genetic lesions in malignant epithelial cells and in the
stromal background in clinical trial design and during the
selection of patients for therapy. Expression profiling at the
mRNA and protein level has revealed several subtypes of
breast cancer, and it is important that intracellular and extracel-
lular processes of growth and progression are further explored
in relation to these, both through models that aim to recapitu-
late each class and through representative clinical material.
The non-tumour content of biopsies should also be consid-
ered since evidence is emerging to suggest that this has a sig-
nificant effect on gene expression profiles [66]. Equally,
several studies have indicated the importance of considering
specific lesions in relation to therapeutic response, for exam-
ple, Aurora kinase overexpression and taxane resistance,
BRCA2 loss and response to platinum-based therapy [67],
topoisomerase II alpha amplification and epirubicin response
[68]. Considering these parameters may not only improve
patient stratification for more effective trial design, but may
also allow smaller patient cohorts to be studied, if these are
selected rationally for therapy according to the status of the
drug target or molecular lesion.
Improved research reagents
Better research reagents are needed to continue to accurately
define new pathways in experimental material and to study
clinical samples to verify these pathways as biomarkers in rela-
tion to pathology and outcome.
Signalling mechanisms in clinical samples can be detected
using immunohistochemistry, including the use of phospho-
specific antibodies [69,70]. However, if associations are to be
accurate and meaningful, this urgently requires assays that
have a reproducible, sensitive and specific performance in
such material, incorporating improved quality control as has
been achieved for ERα and HER2 assays [71-73]. Technolo-
gies such as fluorescence resonance energy transfer (FRET)
have the potential to measure interplay between elements (for
example, receptor dimerisation) in such material. However, in
all instances these methodologies will require consensus
regarding evaluation which should also aim for quantitative
analysis, for example, through image analysis. More accurate
quantification may potentially incorporate luminescent quan-
tum dots as an alternative approach to visualise tumour
markers.
Research to reveal new biomarkers and drug targets in exper-
imental and clinical material will also increasingly need to
incorporate high-throughput gene profiling with microarrays
and TMA validation, as well as proteomics. In these latter
areas, quality control urgently needs to be addressed and bio-
informatic capabilities must be significantly enhanced on a
national level if we are to manage and meaningfully interpret
the increasing volume of signalling data that will emerge in
relation to cellular endpoints and clinical outcome.
Research infrastructure
Overcoming these various barriers has obvious implications
for research infrastructure. Studies will need to be increasingly
multidisciplinary if we are to identify relevant determinants of
breast cancer growth and progression; for example, requiring
the integration of multiple expression/signalling studies, bioin-
formatics, imaging technologies, improved in vitro and in vivo
models, genetic manipulation and clinical examination. This
will depend on a backbone of realistic supportive funding, not
only to maintain core strategies and associated quality control,
but to ensure access to new technologies to pursue innovative
research avenues (for example, in vivo imaging, genetically
engineered models and high-throughput genomic screening).
A critical mass of expert staffing is essential, including expand-
ing the breast cancer research talent pool through improved
research training and more clearly structured career develop-
ment. The need for carefully collected and documented clinical
tissue with serial biopsies taken during therapy with defined
treatments, TMAs, samples from distant sites and local recur-
rences made available to investigators is key. Recent legisla-
tive changes have made this more difficult and both surgical
and pathology support are needed at a senior level. Both spe-
cialities have suffered severe cutbacks; collaborative contribu-
tions by academics in these areas are important and deserve
funding, in addition to supporting the highest quality peer-
reviewed independent research.
Pathology training will be increasingly important as we expand
our technical capabilities for investigating clinical material.
Standardisation of antibodies and other reagents is needed to
compare results between investigators. Research would also
benefit from increased sharing of experimental and clinical
resources. Finally, increased investigator-driven studies and
collaboration with industry will be essential if we are to improve
patient recruitment for clinical studies aimed at understanding
biological factors driving selective response.
Translational implications
If research can be tailored to the diverse questions regarding
the intracellular and extracellular processes underlying breast
cancer growth and progression, this should link tumour mech-
anisms to disease classification and prognosis.
To some extent this process is underway through microarray
studies, which have led to the classification of invasive breast
cancer into four categories, luminal, basal, HER2/neu overex-
pressing and normal [74], and the development of various
gene expression signatures that can predict outcome. How-Page 10 of 25
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tify earlier patients at increased risk of dissemination and
therefore allow selection for anti-invasive therapy and, second,
to provide robust biomarkers to effectively predict therapeutic
response with growth inhibitors. Filling the gaps outlined for
very early progression may improve selection of patients with
DCIS for adjuvant radiotherapy or endocrine therapies, while
avoiding unnecessary treatment in others.
Equally, it is likely that we will reveal cellular targets for devel-
oping new agents to target breast cancer progression effec-
tively and selectively (as well as being able to measure the
target pathways dynamically during therapy to monitor clinical
efficacy of novel inhibitors and improve trial design). Together,
successful research should allow therapy to be increasingly
individualised and include combination strategies aiming at
maximally subverting tumour resistance and disease progres-
sion, improving the outlook for patients.
4. Therapies and targets in breast cancer
A summary of the gap analysis for therapies and targets in
breast cancer is given in Table 4.
The treatment of breast cancer has improved over recent years
and has led to an increased survival rate for patients with
tumours confined to the breast. This is partly due to breast
screening resulting in early diagnosis but also the appropriate
selection for patients of the surgical approach, radiotherapy,
chemotherapy regimen and more recent therapies.
What do we know?
The introduction of new therapeutic strategies, including
newer adjuvant endocrine treatments, radiotherapy schedul-
ing, chemotherapy combinations and novel agents such as
trastuzumab, has contributed to the increase in disease-free
and, in some cases, overall survival. However, breast cancer
recurs, sometimes many years after diagnosis, and the treat-
ment of metastatic disease remains palliative. Thus, not all
therapies used are effective and a proportion of patients (per-
haps a majority for some therapies) receive one or more treat-
ments which either are not required or fail to stem the disease.
Selection of multimodality therapy for an individual patient by
a multidisciplinary team is based on the extensive evidence
base for individual and combination therapies summarised
elsewhere.
Table 4
Summary of the gap analysis for the therapies and targets in breast cancer
What do we know? The selective use of combinations of surgery, radiotherapy, chemotherapy, and biological therapies has improved 
patient survival in recent years.
Not all therapies used are effective on all patients.
What are the gaps? There is an incomplete understanding of the biology of breast cancer including the effects of compensatory signalling 
pathways responsible for drug resistance.
We cannot determine who goes on to develop metastatic disease or drug-resistant cancers.
Individualisation of therapies could be improved.
The optimal duration of therapy is unclear for many drugs.
Problems There are insufficient model systems for the complexity and diversity of breast cancer.
The need to understand not only the cancer, but the tumour microenvironment and patient characteristics (including 
drug metabolism and immune mechanisms).
Availability of clinical material is scarce, particularly from metastatic disease tissues.
The neoadjuvant model could be used more effectively.
Translational implications Patients could be selected for appropriate therapy more effectively.
Enhanced understanding of the sequencing, combinations and duration of treatments.
Recommendations Build resources through high-quality, uniform, multicentre collection of clinical material from breast cancer patients 
before and during treatment (including neoadjuvant studies), including samples of primary tumours as well as 
metastatic deposits.
Develop methods for easy, reproducible monitoring of response to and development of resistance to therapy, as well 
as early disease progression.
Increase research efforts into the role of the tumour microenvironment and the immune system in the development and 
treatment of breast cancer.Page 11 of 25
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Incomplete understanding of the biology of breast cancer
Our understanding of the many cellular and molecular proc-
esses involved in the development of breast cancer is still
incomplete. This hampers the identification of new therapeutic
targets as well as the optimal use of the targets we know
about. We have limited knowledge of which signals drive
breast cancer cell growth, and how they promote the invasive
nature of the disease. In addition, the role of the surrounding
healthy tissues in tumour development, both at the primary and
metastatic sites, needs to be clarified.
Current thinking is that to eradicate cancer cells we may need
a combination of therapies targeting the tumour cells, their
microenvironment and, potentially, their blood supply.
We cannot determine who goes on to develop advanced 
disease
Despite our best efforts a proportion of patients will develop
advanced disease, and we do not currently have reliable tools
to predict who these patients are. By using tumour grade,
pathological node status, tumour size and other pathology fea-
tures, a number of models have been designed to assess the
risk of patients developing metastatic disease including the
Nottingham Prognostic Index and Adjuvant Online. However,
there are no established molecular markers used in clinical
practice to determine with certainty whether a breast tumour
is likely to metastasise to other sites, and therefore no easy
way of selecting patients at early stages of the disease that will
require more intensive treatment to prevent tumour
progression.
In addition, there are no simple, non-invasive methods availa-
ble for detecting the early stages of tumour progression, and
patients often present with relatively advanced (symptomatic)
disease.
Insufficient knowledge to provide precise, individualised 
therapies
One of the main problems when treating breast cancer is to
determine which patients will benefit from particular therapeu-
tic strategies, ensuring optimal results for each individual
patient. Not only is this key to achieving the best possible
outcome for patients who are likely to respond to any given
treatment, but also to avoid treating those who will not benefit.
A few targeted treatments are available (for example, endo-
crine treatments and trastuzumab) that rely on identifying a
receptor present on the tumour cells. Understanding the biol-
ogy of breast cancer better is likely to help us develop new
anti-cancer agents that effectively target specific receptors
present in only a subset of patients.
In addition to the biological characteristics of the tumours,
each patient has an individual capacity to metabolise drugs.
This leads to variations in drug half-life that may partly explain
why the response rate varies between patients receiving iden-
tical treatments. For example, many commonly used anti-can-
cer agents (including cisplatin, doxorubicin, tamoxifen and
etoposide) are metabolised in the liver by enzymes of the p450
group, and there are documented variations in the activity of
these enzymes between individuals.
Finally, the optimisation and combination of the current thera-
pies to fit individual patients is often based on a trial and error
approach, rather than a clear understanding of the biology of
the tumour.
How to decide when to stop treatment?
We lack suitable methods for the early determination of recur-
rence and treatment failure.
For most current therapies, there is little long-term data to sup-
port when it is safe to stop treatment. If patients experience no
side-effects and are free from cancer they are likely to want to
continue their therapies even in the absence of any proven
benefit. There are no easy, non-invasive, reproducible methods
available for routinely monitoring subclinical disease progres-
sion and response to adjuvant treatment, and we rely on
patients to present with symptoms in order to establish
whether the tumour has recurred.
Who will develop drug-resistant tumours?
The basis of drug resistance is not well understood, and as a
consequence we have no reliable methods of predicting who
will go on to develop resistance to the commonly used thera-
pies. We do not know how to avoid a resistant phenotype
developing, and is it not clear whether changes in the fre-
quency of drug administration and/or length of treatment con-
tribute to this process.
Incomplete understanding of the role of the immune system
We do not fully understand how best to use the immune sys-
tem to our advantage in breast cancer treatment, either as a
vaccine or in the form of immunotherapy. The lack of suitable
model systems for studying the immune response, as well as
the many fundamental differences between the species most
commonly used (rodents) and humans have hampered
progress in this area. In addition we also lack understanding of
how tumour cells suppress the immune response to ensure
their survival and growth.
How do anti-cancer treatments adversely affect cancer 
cells?
Experimentally, it is becoming apparent that treatment of
breast cancer cells with endocrine therapies can rapidly acti-
vate alternative signal transduction pathways, which may limit
the initial anti-tumour response, allow resistance to develop
and, ultimately, encourage invasive behaviour [75]. For exam-
ple, EGFR/HER2 signalling is triggered by anti-oestrogens inPage 12 of 25
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tain residual downstream kinase activity, proliferation and cell
survival [76]. Interestingly, 'compensatory' induction of alterna-
tive signal transduction is a phenomenon shared by other
types of anti-cancer therapy, including anti-growth factors,
chemotherapy and radiotherapy [77-79].
The full breadth and cellular impact of such compensatory sig-
nalling is largely unknown in breast cancer. To fill this gap we
need to use high-throughput discovery tools to profile multiple
signalling pathways and to explore the concept in a broader
panel of models reflective of the various breast cancer sub-
types. In addition, although changes in some signalling
elements (for example, HER2, activity of various kinases
including MAPK, JNK and p38) have been reported to be in
place by the time of relapse, the drug-induced concept is
largely unexplored in patients. We need increased access to
'on therapy' clinical samples to rectify this.
What are the problems?
There are many reasons for these gaps in our knowledge,
including the following: A lack of suitable model systems
reflecting the complexity and diversity of breast cancer; Lim-
ited access to clinical material from patients before and, in par-
ticular, during treatment; A severe lack of material from
metastatic deposits made available for studies of target hits
and biological response to therapies.
The neoadjuvant model provides a window of opportunity
where therapy can be tested in vivo in humans to assess the
effects of an intervention. It allows biological evaluation of
tumour markers and normal tissue responses by histological,
biochemical, molecular, imaging or clinical techniques. How-
ever, neoadjuvant studies have not usually involved adequate
numbers of patients for what can be intensive study and indi-
vidual centres often recruit too few patients in specific groups
to ensure meaningful analysis; a multicentre approach is
required to ensure progress.
Identifying new therapeutic targets is hampered by our limited
understanding of the role of the tumour microenvironment and
interactions with cancer stem cells in the development and
progression of breast cancer. In addition, we do not
understand the mechanisms underlying the acquired resist-
ance to anti-cancer therapies. There are too few studies
across disciplines to increase our understanding of the role of
the immune system, an area where there is a lack of appropri-
ate model systems and insufficient high-quality studies carried
out in humans. Not enough attention has been paid to how
drug metabolism by individuals affects response to treatment.
This important point is not considered in drug trials on an indi-
vidual basis, or linked to measurements of response, but may
partly explain why there is such variation between patients
receiving identical treatments. As assays for drug metabolising
cytochrome p450s become available (for example, 2D6 for
tamoxifen metabolism), this may move into clinical practice.
These gaps may be filled by developing improved model sys-
tems that seek to reflect the complexity of the human disease,
combined with increased efforts to design multicentre studies
using clinical material collected and processed in a uniform
way. Particular areas that we need to strengthen are the
increased use of neoadjuvant studies, providing researchers
with valuable clinical material from breast cancer patients dur-
ing treatment in the form of repeated biopsies.
Few studies have involved investigations of metastatic depos-
its, so our understanding of the biological changes of the
tumour cells as they adapt to new environments is limited. Not
many patients will undergo procedures that allow the collec-
tion of material from metastatic sites, and no single centre is
likely to be able to collect significant numbers of quality spec-
imens for research. As building these types of 'biorepositories'
for future research is likely to take many years to accumulate
numbers that allow meaningful data analysis, this requires a
collaborative, long-term approach for which funding may be
difficult to obtain (most funding bodies operate on a three- to
five-year timescale before results are expected).
We therefore see an urgent need for high-quality, comprehen-
sive, longitudinal sample collections (tumour, DNA, serum,
plasma, urine) from breast cancer patients, coupled with
extensive clinical information. Where appropriate, collabora-
tions with researchers in other fields (for example, immunolo-
gists working in rheumatology or auto-immune diseases) are
needed.
Translational implications
If we could fill the gaps identified here we anticipate that we
would be able to select patients for appropriate therapy more
accurately, start patients on therapies earlier and monitor
progression and response. We would have a better under-
standing of how to sequence and combine therapies, an
increased capacity to develop innovative and immunologically
based therapies that subsequently prove suitable for treating
the disease. For example, proof of principle experimental data
reveal that intelligent targeting of induced signalling alongside
the primary therapy can achieve a previously unobtainable
level of cancer cell kill and substantially improve anti-tumour
response [76]. If the drug-induced concept is reproduced in
vivo, rationally designed combination strategies could have
the potential to improve initial response and delay resistance
and progression; this would have a positive impact on breast
cancer survival rates. We would then be better placed to
develop drugs with an improved therapeutic window and
fewer side-effects, and be able to improve breast cancer sur-
vival rates.Page 13 of 25
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A summary of the gap analysis for disease markers in breast
cancer is given in Table 5.
Developing new treatments for breast cancer and refining
existing regimens are clearly important and exciting areas of
research. The challenge is to ensure that new therapies reach
the patients who will benefit most, and to identify patients for
whom the harms outweigh the benefits or for whom the
treatment will be ineffective [80]. To achieve these aims we
need validated predictive and prognostic markers.
What do we know?
The gold standard for comparing new markers is testing
against high-quality pathological assessment of tumour type,
size, grade and lymph node stage.
Only two markers have been established so far in the routine
assessment of breast cancer: ER (for predicting response to
endocrine therapies) [80]; HER2 (for predicting response to
trastuzumab) [80,81].
Although theses markers for predicting the response to endo-
crine and biological therapies are already available, even ER
and HER2 are far from perfect; for example, assessment of
HER2 status will still include some non-responding patients
[81].
Intelligent trial design involving multidisciplinary teams is
essential to ensure new treatments are tested in patient
groups stratified using biomarkers. Large-scale studies of
invasive breast cancer that have and are using these principles
successfully include the trials of trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer [81]. Biomar-
ker-based trials may also be used to assess treatments for
advanced breast cancer, but may be confounded by prior
exposure of such cancers to multiple therapies.
Ideally, however, pre-operative (neoadjuvant) studies are
required, using clinically relevant models and crossover
designs to provide early evidence of a therapeutic effect and
to differentiate responsive from non-responsive groups of
patients [82].
What are the gaps?
Innovative trial and study design
Disease marker concepts should be applied to trials of treat-
ments for pre-invasive disease including DCIS and to models
of sentinel lymph node assessment, where funding is limited
and where long-term follow-up is required to obtain robust
clinical data, but where we need a better understanding of the
pathophysiological processes involved. Two areas we need to
address are as follows: The level of sentinel lymph node
involvement that has a clinical impact; Optimum protocols for
Table 5
Summary of the gap analysis for disease markers in breast cancer
What do we know? Patient groups can be successfully stratified in clinical trials using biomarkers.
What are the gaps? Optimum protocols for pathological assessment of DCIS and sentinel lymph nodes.
Combining clinical, radiological, pathological and genomic data in trial populations.
No robust validated markers have yet been developed for predicting response to chemotherapy or radiotherapy.
There is no consensus for markers indicative of resistance to therapy.
There is a need for improved prognostic indices based on disease markers.
Problems New assays must be robust and reproducible.
There is a need for standardisation of tissue handling.
The impact of legislation, industrial involvement and academic pressures.
Networks of collaboration employing systems biology are required.
Translational implications Accurate recognition of the diversity of breast cancer.
Identification of patients most likely to benefit.
Identification of patients least likely to benefit from therapy and hence able to avoid toxicity.
Recommendations Design innovative trials and translational studies to develop and evaluate predictive and prognostic markers.
Develop close multidisciplinary collaboration with high-quality histopathology and rigorous scientific assessments to 
validate new markers important for patient outcome.
Identify robust markers of resistance or sensitivity to therapy that can be applied across the spectrum of breast 
disease from screen-detected to metastatic breast cancer.Page 14 of 25
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[83].
Additional challenges include recognising the differences
between laboratory studies and in vivo studies in humans
where interactions between tumour and stroma, three-dimen-
sional effects and vascularisation become relevant. Further-
more, combining clinical, radiological, pathological and
genomic data in trial populations with innovative trial designs
(such as in the MINDACT trial [84]) will allow us to relate, com-
pare and combine established markers to, and with, new tech-
nologies in a range of settings. Success depends on close
multidisciplinary collaboration at an early stage, as well as the
highest quality histopathological and scientific evaluation.
Validating new markers
New markers may be best validated in trials of neoadjuvant or
adjuvant therapies and in advanced disease, where clinical
data and outcomes are robust and statistically significant.
However, large numbers of patients may be required for small
incremental differences in outcome.
The key question is: does introducing a new marker change
clinical practice and therefore patient outcome? In the past,
researchers have not paid enough attention to experimental
design when assessing this; consequently the results have not
always been standardised, reproducible or robust enough to
apply to clinical practice. Developing rigorously controlled rea-
gents, technical methods and appropriate interpretation
requires adequate resources and to date this has rarely been
forthcoming.
While ER-negative patients rarely respond to hormone thera-
pies, a proportion of those classified as having ER-positive dis-
ease will also not respond [85]. No robust validated markers
have yet been developed for predicting response to chemo-
therapy or radiotherapy. Many markers are favoured by local
enthusiasts (for example, progesterone receptor [PgR], PS2
and cathepsin D) but we need high-quality clinical evidence to
support their more widespread use.
Markers indicative of resistance to therapy (for example, ER-
positive, PgR-negative tamoxifen-resistant cancers) have been
proposed, but there is little agreement about methodology or
cut-offs of scores for clinical application, or indeed their overall
value. In addition, some markers may not be useful once regi-
mens or therapies are superseded. We therefore need to com-
pare, and potentially combine, markers such as the ER and
PgR with pathological markers (such as histological type,
grade and node metastasis), which have prognostic impor-
tance. Funding for robust studies evaluating these markers is
crucial, but is rarely achieved without financial support from
the pharmaceutical industry.
Researchers have identified validated intermediate endpoints,
such as the effects on apoptosis, proliferation and ER down-
regulation (for example, with fulvestrant therapy). However, fur-
ther work is urgently needed using tumour pathology (for
example, lymphovascular invasion and microstaging) and
molecular biology, and exploring the potential of disease
response markers, such as serum proteomic markers and cir-
culating tumour cells. Subclass-specific markers based on
microarray approaches have been identified and validated by
immunohistochemistry [86,87], but have yet to be applied in
clinical trials and clinical practice.
Therefore, although breast cancer can be classified according
to histology and expression of RNA and protein, for example,
into basal, HER2, luminal A and luminal B and normal breast-
like subtypes [86,87], we need to develop this further to pre-
dict the prognosis of each subtype and the likelihood of
response to therapies.
A further challenge is in understanding the complex factors
influencing prognosis and in improving the quality control of
reagents used in new technologies (such as proteomics,
phosphoproteomics, epigenetics and assays of microRNA) so
that they can be effectively applied to routinely available clini-
cal material. In particular, integrating old and new methods and
combining techniques (such as TMA, immunohistochemistry,
fluorescence in situ hybridisation, data storage and analytical
methods) may allow us to develop new composite prognostic
indices. A significant challenge to the development and valida-
tion of predictive markers is counteracting the effects of stor-
ing tumours and blood derivatives on proteins (including
phosphorylated proteins) and in proteomic studies. We clearly
need careful research into these processes and how to take
them into account.
What are the problems?
Any new assays that are developed must stand up to the day-
to-day challenges of clinical practice. The quality of service
delivered in routine clinical practice varies, even for basic
markers such as ER and HER2 [88]. RNA-dependent assays
have been considered less robust than protein- or DNA-based
assays in the breast cancer setting. However, RNA-based
polymerase chain reaction (PCR) technology may well
become a standard of care as an intra-operative detection
method for tumour in sentinel lymph nodes. Techniques must
undergo regular quality assurance both during development
(in the research setting) and in subsequent laboratory and clin-
ical use; marker validation requires time and resources and
subsequently convincing the professions to apply them.
Implementing advances in molecular understanding may be
limited to paraffin tissues as a source of standardised and sta-
ble processed material in the foreseeable future. Advances
rely on having appropriate technologies and tissues available
and on training for scientists and clinicians. The timing andPage 15 of 25
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critical both in trials and in routine clinical use. Clinical trials
have rarely developed standard procedures for collecting and
documenting tissue, although more recent innovative trials do
so [84]. Even then, delivery time and costs may prevent tech-
niques and markers from being widely used in clinical practice.
Smaller cancers, often detected by breast screening, present
particular problems. Not only may there be little material for
studying the primary tumour, but lymph node micrometastases
are more likely to be present than larger deposits and may
change the classification of nodal status. Such patients may
still have an excellent prognosis, although conventional indices
relating node involvement to disease behaviour may result in
adjuvant (over) treatment being given.
Additional issues influencing the development, choice and use
of markers include the impact of legislation (such as Good
Clinical Practice and Good Laboratory Practice) and ethical
approval processes on the funding, management, ownership
and access to tissue collections and associated clinical data.
Academic pressures (particularly the influence in the UK of the
Research Assessment Exercise) may be counterproductive to
collaborative translational research, which should (but may not
be) recognised as of high value.
Translational implications
Integrating established and new approaches to prediction and
prognosis continues to present challenges. Networks of col-
laboration (for example, tissue banking and collection of linked
patient, tumour and molecular data) employing systems biol-
ogy (for example, information technology, modelling, identifica-
tion of key nodes) are still needed for breast cancer research,
despite UK and European initiatives. Such developments
could speed the development, testing and implementation of
new methods of detection and markers of disease behaviour.
We need to recognise the diversity of breast cancer using
both traditional and new markers to individualise therapy. Tra-
ditionally, trials have classed all women with breast cancer as
a single population with a single disease and many have
focused on women who have a good prognosis. Future stud-
ies should also investigate other groups, such as women least
likely to benefit from adjuvant therapy and those with a higher
risk of relapse. Targeting breast cancer therapies to those
most likely to benefit and avoiding treatment in patients or
tumours not responsive could significantly focus benefits on
patients likely to respond but also prevent avoidable toxicity.
6. Prevention of breast cancer
A summary of the gap analysis for the prevention of breast can-
cer is given in Table 6.
Prediction and primary prevention of breast cancer
What do we know?
Several large-scale randomised controlled trials show that
endocrine chemoprevention for oestrogen-responsive
tumours works [89,90]. Breast cancer prevention pro-
grammes need to target women at highest risk. Risk prediction
programmes predict how many cancers will occur in a popula-
tion [91], but we need to improve their specificity. We cur-
rently need to treat 50 'high-risk' women to prevent one
cancer.
Observational studies define mammographic density as one of
the strongest risk factors for breast cancer (relative risk 4.64
(3.64 to 5.91) >75% relative to <5% density) [92]. Expert
opinion suggests that 20% to 80% of risk is linked to diet [93].
Measurement error with accepted diet assessment methods
(food frequency questionnaires) may, however, fail to correctly
identify dietary risk factors. For example, recent studies using
food diaries, but not food frequency questionnaires, have
linked dietary fat to risk [94,95]. Gene-environment (diet) inter-
actions are a further complexity. Failure to consider genotype
may mask significant associations with diet; likewise, the
effects of genetic polymorphisms may be detectable only with
specific dietary exposures (that is, the effect of dietary isofla-
vone intake on levels of sex-hormone binding globulin among
women with the N-variant of the D356N gene) [96].
Observational data link weight gain to the risk of post-meno-
pausal breast cancer and lack of exercise to both pre- and
post-menopausal breast cancer. Weight loss before and after
the menopause reduces post-menopausal risk by up to 40%
[97,98]. The observational nature of these studies means that
the independent effects of energy restriction, exercise or
reductions in adiposity on risk reduction are not known.
What are the gaps?
The long-term effects of chemoprevention for ER-positive
tumours (beyond five-year study periods) are not known, while
preventing ER-negative tumours remains a challenge. Key
research areas to inform the development of chemoprevention
agents include understanding the target cell (stem or ER-neg-
ative cells) and the target lesion in the breast (hyperplasia,
atypical ductal hyperplasia, hyperplastic enlarged lobular unit
or DCIS) and why the ER becomes deregulated. We need
short-term intervention studies of preventive agents and strat-
egies, using pre- and post-intervention biopsies and fine nee-
dle aspirates (Ki67, ER).
Risk prediction models need to be improved by including mod-
ifiable risk factors, such as mammographic density and life-
style factors. Key problems that need to be resolved regarding
breast density are what mammographic breast density actually
measures and whether it is absolute or percentage breast den-
sity that is most related to risk. Prospective studies of breast
density (using standardised methods) and demographic (bodyPage 16 of 25
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(that is, age and lifestyle factors, and weight) that modify
breast density, and whether these modify the relationship
between density and risk.
Elucidating the role of diet in the aetiology of breast cancer
requires prospective study of diet and genetic variation, using
sensitive dietary assessment methods (food diaries). The rela-
tive effects of energy restriction, exercise and reduced adipos-
ity on risk are unlikely to be determined from epidemiology and
need to be unravelled by short-term controlled biomarker trials.
In addition, the role of adipose tissue and its secretory prod-
ucts (oestrogen and adipokines) in breast cancer develop-
ment and progression need to be examined from laboratory
studies. Since weight loss is difficult to achieve and maintain,
effective weight-loss strategies and the benefits of energy
restriction mimetic for cancer prevention need to be deter-
mined [99]. Psychosocial research is required to explore the
health beliefs of high-risk and population-risk women, and to
determine their potential interest in lifestyle or pharmacologi-
cal strategies for breast cancer prevention.
What are the problems?
Accrual and retention in prevention trials is a problem; there is
currently around a 10% uptake and a 30% dropout rate. Bet-
ter risk prediction would enable recruitment to be targeted at
women with higher levels of risk and motivation. We also need
to make the public aware of the cancer prevention message
(as with the Know Your Gail Score campaign in the USA). We
need more diverse recruitment to studies in terms of age and
ethnicity.
Transdisciplinary input is needed within prevention trials (for
example, geneticists, epidemiologists, nutritionists, psycholo-
gists and clinicians) to study the psychosocial, compliance
and genetic aspects of prevention.
Table 6
Summary of the gap analysis for the prevention of breast cancer
What do we know? Endocrine chemoprevention for oestrogen-responsive tumours works.
Key risk factors include mammographic density, post-menopausal weight gain, high-calorie, high-fat diets and lack of 
exercise.
Breast screening is effective. MRI screening is more sensitive than mammography for high-risk women
Epidemiological data suggest weight control, low-fat diet and exercise after diagnosis improves outcome of early 
breast cancer patients.
What are the gaps? The long-term effects of chemoprevention of ER positive cancers are unknown.
Prevention of ER-negative cancers remains a challenge.
There is a need to understand the target cell for breast cancer prevention.
Need to improve current risk prediction models by including modifiable risk factors.
The health beliefs of high-risk and population risk women require exploration.
The effects of breast screening out with currently targeted groups is not known.
To define deliverable diet and exercise interventions for the primary and secondary prevention of breast cancer.
To elucidate the mechanism for breast cancer prevention with energy restriction.
Problems Accrual and retention of women in prevention trials.
Better models to research new chemoprevention agents.
Breast screening lags behind advances in imaging technology.
Poor uptake to diet and exercise trials after diagnosis.
Translational implications Better identification of high-risk women would allow chemoprevention to be targeted more effectively.
Defining optimum screening methods will ensure more effective use of limited NHS resources.
The development of energy-restriction mimetics for breast cancer prevention.
Optimal diet and exercise interventions could improve quality of life and outcome for women with breast cancer.
Recommendations Improve breast cancer risk prediction models.
Encourage transdisciplinary input to prevention trials (for example, geneticists, epidemiologists, nutritionists, 
psychologists and clinicians) to study the psychosocial, compliance and genetic aspects of prevention.
Establish the potential benefits of diet and exercise post-diagnosis on outcome and quality of life for breast cancer 
patients.Page 17 of 25
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tion agents, such as stem cell progenitor assays and human
breast tissue in nude mice, and better surrogate markers of
breast cancer risk. Further mammographic density research
requires standardised methods of measurement that need to
keep pace with technology in breast screening (for example,
digitised mammography and computer-aided detection
programmes).
Funding is an issue because prevention and psychosocial
research has not been a high priority. Intervention studies are
labour intensive and often require more funding than basic sci-
ence research or than that currently available in project grants.
Translational implications
Identifying women who are at high risk of developing breast
cancer would enable clinicians to target chemoprevention
more effectively. Likewise, unravelling the links between diet
and lifestyle, genetic variation and risk would enable us to tar-
get lifestyle cancer prevention strategies at the women who
would benefit most. Elucidating how lifestyle factors influence
risk would underpin an evidence-based lifestyle cancer pre-
vention message, and may enable us to develop drugs that
mimic their effects (that is, energy restriction mimetics).
Breast screening
What do we know?
Breast screening using mammography reduces mortality from
breast cancer in women older than 50 (see [100]), and there
is limited evidence among women at high risk of breast cancer
(lifetime risk of more than 1:6) aged 40 or older [101-103].
Contrast-enhanced magnetic resonance imaging (MRI) is
more sensitive than mammography for detecting cancer in
high-risk women [104].
What are the gaps?
We do not know the benefits of screening women younger
than 40 or whether MRI reduces mortality from breast cancer
among high-risk women. We also need to determine whether
the newer 3 Tesla MRI machines are more sensitive than the
1.0 to 1.5 Tesla MRI machines that were used in earlier stud-
ies. We need to conduct further studies to define the best sur-
veillance method for women with dense breasts, women at
high risk and women who have had breast cancer, and con-
sider the potential for using other techniques, such as ultra-
sound or infrared imaging, to screen these women.
What are the problems?
Research needs to keep pace with improving imaging technol-
ogy. There are few data on the uptake of women older than 70
to the National Breast Screening Programme. The recent
decline in attendance for screening in the general (eligible)
population suggests we need to explore women's health
beliefs regarding breast screening. For example, does attend-
ing screening negate women's interest in prevention strate-
gies because many women perceive screening as prevention?
Translational implications
Defining optimum screening methods in different populations
may save lives and ensure more effective use of limited
resources within the NHS.
The importance of diet and exercise after a diagnosis of 
early breast cancer
What do we know?
Weight, diet and exercise all have an impact on outcome after
a diagnosis of breast cancer. Many breast cancer patients are
overweight at the time of diagnosis, while many more gain
weight after diagnosis, which may increase their risk of dying
from breast cancer [105,106] or from weight-related co-mor-
bidities [107] (for example, cardiovascular disease and other
cancers). Recent data from a randomised controlled trial (the
Women's Intervention Nutrition Study (WINS)) in the USA
reported a 24% improved relapse-free survival over five years
among post-menopausal breast cancer patients following a
low-fat diet (commenced within the first year of diagnosis),
compared with the group receiving usual care [108]. Since
weight control occurred alongside this low-fat diet it is unclear
whether low fat or weight control was linked with improved
survival in this study.
The feasibility of following a low-fat diet among breast cancer
patients has been piloted in the WINS UK study, where 50%
of breast cancer patients achieved a low-fat intake (less than
20% energy from fat) [108]. Observational data link exercise
after diagnosis (more than 3 hours per week) with improved
survival [109]. A recent systematic review linked exercise dur-
ing and after treatment to improved physical function and
reduced fatigue, while benefits in quality of life were mainly
seen in the post-treatment phase [110].
What are the gaps?
The data on weight and outcome have come from historic
cohorts. The effect of weight and weight gain on outcome
alongside current adjuvant therapies needs to be determined.
We need to define deliverable diet and exercise interventions
after diagnosis, and the optimum timing and mode of delivery
for interventions need to be derived from high-quality ran-
domised controlled trials both during and after treatment.
Improved breast cancer survival among recent cohorts shifts
the focus to co-morbidities. However, there are few data on
the prevalence of co-morbidities or their effect on outcome.
What are the problems?
There has been a poor uptake to diet and exercise trials post-
diagnosis. More patient-centred qualitative studies are needed
to establish preferences along with barriers and motivators to
changing behaviour after diagnosis. The feasibility of deliveringPage 18 of 25
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is a potential concern. Healthcare professionals need to 'buy
in' as diet and exercise traditionally are not priorities among
breast cancer teams.
We also need to consider potential funding, attitudes and
work pressures of healthcare professionals, to decide who is
best placed to deliver interventions. Good biomarkers of
prognosis and measurements of quality of life among breast
cancer patients need to be defined so we can evaluate the
effect of diet and exercise interventions in trials.
Translational implications
Optimum diet and exercise interventions may improve out-
comes and quality of life for people with breast cancer.
7. Psychosocial aspects of breast cancer
A summary of the gap analysis for the psychosocial aspects of
breast cancer is given in Table 7.
Primary prevention of breast cancer: psychosocial aspects 
of risk and prevention
Genetic testing offers psychosocial benefits for many women
at high risk of developing breast cancer, but patients' percep-
tions of risk are often inaccurate and while many methods have
been used to communicate information about risk, they do not
always improve patients' understanding [111].
What do we know?
Research into the psychosocial impact of bilateral risk-reduc-
ing mastectomy is limited, but suggests that while women may
be satisfied with their decision to undergo surgery, they may
report dissatisfaction with their body image afterwards. Most
women are less worried about cancer after surgery, but this
may be because they overestimate their risk of developing
breast cancer. They need to understand their true risk before
considering mastectomy [112]. There is good evidence that
counselling can improve the accuracy of perceived risk, but to
a varied extent.
Breast screening programmes for women at increased risk do
not increase anxiety in women who do not require further
investigation, but women who are referred for further investiga-
tions are evidently more anxious [113].
What are the gaps?
Exploring issues around cancer genetics is paramount, such
as follow-up studies of carriers who have or have not under-
Table 7
Summary of the gap analysis for the psychosocial aspects of breast cancer
What do we know? There are psychosocial effects of genetic testing, prophylactic mastectomy and breast screening.
Descriptive studies of the experiences of breast cancer patients using quantitative and qualitative methods show 
women still experience psychosocial distress despite improvements in treatment and prognosis.
Psychosocial interventions have been shown to benefit women, including those identified as experiencing high levels 
of distress.
What are the gaps? Evaluation of decision aids for risk management and the choice of preventative surgery amongst high-risk women.
Ways of effectively communicating information and aiding patient treatment decision-making.
Defining patient experiences in early, chronic and end stage breast cancer.
Limited research into co-morbidities amongst breast cancer patients.
Experiences of ethnic minority populations and older women.
The need to develop and evaluate appropriate psychosocial interventions for high-risk women and those diagnosed as 
having breast cancer.
Use of psychological theories in behaviour change that could enhance compliance to lifestyle and chemoprevention 
trials.
Problems The need for the long-term follow-up in psychosocial research.
Barriers to the uptake of research findings.
Translational implications Direct improvement in the experience of patients, their families and those at increased risk.
Recommendations Develop and rigorously evaluate appropriate psychosocial interventions.
Encourage cross-speciality collaboration to incorporate psychosocial issues and psychological theory (for example, 
psychological theories in relation to behaviour change are relevant to those researching prevention with diet and 
exercise or chemoprevention).
Ensure research gives greater attention to all stages of breast cancer and that the needs of older women and those 
from a range of ethnic groups are included.Page 19 of 25
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needed into the impact of different modes of risk counselling
on perceived risk accuracy, healthcare behaviour and uptake
of risk-management options. We also need to develop and
evaluate decision aids for risk management and choice of sur-
gery. Research also needs to examine further the effect of
communicating risk among partners and families of women
diagnosed or identified as having an increased chance of
developing the disease.
After diagnosis: psychosocial aspects for patients with early 
and advanced disease
What do we know?
Areas currently well supported include descriptive studies of
the experiences of patients, carers, family and partners
[114,115]; the comparative impact of mastectomy versus con-
servative surgery [116] and of breast reconstruction [117];
aspects of doctor-patient communication [118,119]; recogni-
tion of the need to include quality-of-life evaluation in cancer
treatment trials; return to work after treatment [120] and
potential benefits of exercise on quality of life [121]. This
research has fruitfully employed both quantitative and qualita-
tive methods to demonstrate that biomedical developments
are not a panacea for the psychosocial distress associated
with the disease. Psychosocial interventions have been shown
to benefit distressed patients, but are of less value in patients
unselected on grounds of psychological functioning [122].
What are the gaps?
It is imperative that psychosocial research keeps pace with
developments in biomedical treatment and care, including the
surgical and adjuvant options that are available (for example,
new surgical procedures for reconstructive surgery and devel-
opments in hormone therapy), ways of effectively communicat-
ing information about these options and aiding patient
decision-making where appropriate. An evaluation of self-help
strategies is warranted and we also need to broaden the
research agenda beyond psychological distress to include
interventions for body image and sexual problems.
Research has identified patients' priorities for future research,
namely the impact of cancer on life (how to live with cancer),
risk factors and causes, early detection and prevention [123].
Psychosocial research currently focuses on early and end-
stage breast cancer, yet most patients are not under the care
of a palliative team and have to live with their disease and the
symptoms of adjuvant treatment (for example, bone pain, neu-
ropathy, physical changes to appearance) as a chronic condi-
tion. The experiences of patients in this situation are a
significant gap in our knowledge. Future research therefore
needs to consider breast cancer in terms of three periods,
early, chronic and end, and to examine the specific needs of
patients associated with each stage [123]. The specific sup-
port needs of both breast cancer patients and their families fol-
lowing the diagnosis of recurrence also warrants further
research [124].
There is only limited research into co-morbidities, yet cancer is
rarely experienced in isolation and many patients are faced
with the effects of the disease alongside other, often chronic,
health conditions. We need to investigate how to provide
appropriate psychosocial care for patients in this situation.
Topics and issues relevant to both preventative and post-
diagnosis research
What do we know?
There is now a significant body of research into the many psy-
chosocial issues surrounding breast cancer. This research has
employed a range of research methods to explore patients'
experiences both before and after diagnosis. Although the
psychosocial impact of breast cancer diagnosis and treatment
has been increasingly recognised by researchers and clini-
cians in recent years, there is still great potential for psychoso-
cial research to inform the provision of care and improve
patients' experiences.
What are the gaps?
Existing research into both preventative and post-diagnosis
issues is predominantly focused on the experiences of white
women in the UK and USA with a fluent understanding of Eng-
lish. We urgently need additional research into the experi-
ences of breast cancer patients from a broad range of ethnic
minority populations and of those who do not fully understand
English so that tailored care can be provided. Similarly, the
experiences of older women are under-represented.
While we have identified the nature of many psychosocial
issues faced by patients, there is a pressing need to develop
and rigorously evaluate appropriate psychosocial interven-
tions. These should include tools to help patients make
decisions, optimal methods for communicating risk, ways of
dealing with the effects of treatment and return to work and
support for healthcare staff at risk of burnout. Research in this
area can identify the most effective means of delivering cost-
effective, accessible interventions (for example, timing of inter-
ventions, roles of healthcare professionals in delivering inter-
ventions, comparing group and individual interventions, and
using developments in technology for providing information
and decision-making).
Cross-specialty collaboration in breast cancer research that
incorporates psychological theory should be a priority. For
example, psychological theories in relation to behaviour
change could enhance research into diet, exercise and chem-
oprevention interventions so that factors influencing uptake
and adherence are examined.Page 20 of 25
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A number of issues relating to the methods currently employed
in psychosocial research should be addressed. These include
a need for longer-term follow-up of the impact of surgical pro-
cedures and risk counselling, to develop appropriate valid and
reliable measures, to consult patients about research priorities
and to involve a wider range of research participants (see
above). The limited funding available for psychosocial
research is a problem and limits the duration of follow-up and
prospective studies, especially for trials of psychological
interventions.
Table 8
Gap analysis recommendations and future directions
Generic needs Improved preclinical models.
Access to appropriate and annotated clinical material.
Cross-disciplinary working.
1. Genetics of breast cancer Encourage development of research techniques to allow integrated analysis of sequence-level, epigenetic 
and large-scale somatic changes.
Engage in national initiatives for activities such as high-throughput re-sequencing and UK controls.
Encourage research involving intermediate phenotypes.
2. Initiation of breast cancer Develop three-dimensional cell culture models, containing multiple cell types, which reflect the tissue 
architecture of the normal and diseased breast.
Generate better animal models, particularly for ER-positive tumours, in which gene expression can be 
manipulated in all cell types of the mammary gland and will not be altered by transdifferentiation or 
dedifferentiation.
Gain a greater understanding of the genetic changes that occur within atypias and DCIS.
3. Progression of breast cancer Improve preclinical models, research reagents and technologies (including imaging).
Enhance access to appropriate clinical material, including sequential samples obtained during treatments 
extending to new agents.
Consider genetic signature/specific genetic lesions when exploring progression biology and designing 
clinical trials.
4. Therapies and targets in breast cancer Build resources through the high-quality, uniform, multicentre collection of clinical material from breast 
cancer patients before and during treatment (including neoadjuvant studies), including samples of primary 
tumours as well as metastatic deposits.
Develop methods for easy, reproducible monitoring of response to and development of resistance to 
therapy, as well as early disease progression.
Increase research efforts into the role of the tumour microenvironment and the immune system in the 
development and treatment of breast cancer.
5. Disease markers in breast cancer Design innovative trials and translational studies to develop and evaluate predictive and prognostic 
markers.
Develop close multidisciplinary collaboration with high-quality histopathology and rigorous scientific 
assessments to validate new markers important for patient outcome.
Identify robust markers of resistance or sensitivity to therapy that can be applied across the spectrum of 
breast disease from screen-detected to metastatic breast cancer.
6. Prevention of breast cancer Improve breast cancer risk prediction models.
Encourage transdisciplinary input to prevention trials (for example, geneticists, epidemiologists, 
nutritionists, psychologists and clinicians) to study the psychosocial, compliance and genetic aspects of 
prevention.
Establish the potential benefits of diet and exercise post-diagnosis on outcome and quality of life for 
breast cancer patients.
7. Psychosocial aspects of breast cancer Develop and rigorously evaluate appropriate psychosocial interventions.
Encourage cross-speciality collaboration to incorporate psychosocial issues and psychological theory (for 
example, psychological theories in relation to behaviour change are relevant to those researching 
preventative lifestyles including diet and exercise).
Ensure research gives greater attention to all stages of breast cancer and that the needs of older women 
and those from a range of ethnic groups are included.Page 21 of 25
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research findings, for example by continuing to raise aware-
ness of the importance of psychosocial research and interven-
tions and the potential role that all healthcare staff in both
primary and secondary care can play in providing psychosocial
care [125]. This is important because the essential role played
by specialist nurses in providing psychosocial care and the
facilitation of research in this area is often undervalued in the
NHS.
Translational implications
Further rigorous research in this area could directly improve
the experience of patients, their families and those at
increased risk of breast cancer because their psychosocial
needs would be more appropriately and effectively met at all
stages of their cancer journey.
Conclusion
Research into the pathophysiology, detection, treatment, pre-
vention and psychosocial aspects of breast cancer has pro-
duced a wealth of knowledge and has led to substantial
improvements in the care of people with breast cancer or at
high risk of developing the disease.
This analysis has identified numerous gaps that, if resolved,
could have a substantial impact on the diagnosis,
management and prevention of breast cancer. For progress to
occur, the gap analysis panel has made three key recommen-
dations for each of the seven research areas (Table 8). While
recognising the barriers to achieving these aims, the Breast
Cancer Campaign urges researchers and funding bodies
worldwide to target their resources at these priority areas.
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